Citius Pharmaceuticals Inc

+0.08 (+3.69%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)303.09M
Current PEN/A
Forward PE N/A
2yr Forward PE 7.26
See more stats
Estimates Current Quarter
Revenue$9.8 Million
Adjusted EPS-$0.08
See more estimates
10-Day MA$2.17
50-Day MA$1.92
200-Day MA$1.34
See more pivots

Citius Pharmaceuticals Inc Stock, NASDAQ:CTXR

11 Commerce Drive, 1st floor, Cranford, New Jersey 07016
United States of America
Phone: +1.908.967.6677
Number of Employees: 10


Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. It is currently advancing three proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; CITI-002, which provides anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and CITI-101, which is a bio-absorbable film impregnated with minocycline and rifampin for reducing acute inflammation and microbial colonization of breast tissue expanders used in breast reconstruction surgeries following mastectomies. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.